Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC) who relapsed after prior (neo)adjuvant trastuzumab (T) treatment benefitted from dual blockade with pertuzumab + trastuzumab (P + T) in routine clinical practice.
Major finding: The median progression-free survival was 18.8 months, with comparable outcomes observed in patients with hormone receptor (HR)-positive vs HR-negative BC (18.2 vs 19.4 months) and with visceral vs non-visceral metastasis (18.0 vs 20.5 months). No new safety signals were reported, and 6.1% of patients reported fatal serious adverse events.
Study details : Findings are from the observational, noninterventional, HELENA study including 126 patients with HER2+ metastatic BC who relapsed after prior (neo)adjuvant T treatment and received first-line P + T + chemotherapy.
Disclosures: This study was funded by Roche Pharma AG. Some authors declared receiving personal fees, grants, honoraria, or consulting fees from several sources, and one author declared being an employee and holding stocks in Roche Pharma.
Source: Thill M et al. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: Results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Res Treat. 2022 (Sep 12). Doi: 10.1007/s10549-022-06710-4